BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Blogs » BioWorld MedTech Perspectives » Trust in government: 23 more reasons for suspicions

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / FDA

Trust in government: 23 more reasons for suspicions

Dec. 5, 2013
By Mark McCarty

He’s not the only one who thinks this wayThe number 23 is an interesting number. It’s a prime number, and is the number of pairs of chromosomes in human DNA, but it may also become a number FDA won’t soon forget.

FDA recently issued a warning letter to 23andMe, ordering the company to stop offering its gene testing service pending further evaluations of the tests. Then a petition popped up at the website for the White House to require FDA to back off. The petitioners argue the agency “grossly overstates the risks” associated with the test, adding that consumers understand those risks.

I won’t pretend to know what specifically FDA objects to regarding validation of 23andMe’s tests, so I can’t say whether the agency is overreacting. Still, it’s not first time FDA has been accused of overreach, and won’t be the last.

One of FDA’s biggest PR problems has nothing to do with the agency’s past. The biggest problem might be all the things the federal government has done over the past couple of years that have provoked the American public. One of these is the shutdown showdown between the GOP-led House and the Obama administration, but perhaps more damaging is the NSA surveillance disclosures.

But let’s not forget the spying on journalists by the Department of Justice, the very selective review of conservative 501(c)(3) organizations by the IRS, and the Obama administration’s interpretation and re-interpretation of events in Benghazi. The coup de grace is President Obama’s promise that “you can keep your insurance” despite clear indications he knew better.

All this has fed an appetite for libertarianism like nothing any of us has ever seen, which might not be a bad thing. For instance, libertarian candidates are making a run at the city council for the District of Columbia of all places, and a range of publications are taking notice of a surge in voter identification with libertarian political viewpoints.

All this comes at a time when the usual foreign policy and security challenges are surfacing with regularity, including that mainland China is itching for a fight over the South China Sea. Those in government who feel they know better than the rest of us what’s good for us are not only guilty of supreme hubris, they’re also eroding confidence in government at a time when our security and foreign policy challenges still demand our government’s undistracted attention.

Otherwise, people will die needlessly again.

I recently had an online conversation with a relative who said most Americans are too stupid to know what they need and that hence the balance of power between the public and private sectors must shift toward the public sector to ensure our well-being. That’s precisely the paternalistic attitude behind government overreach. If the citizens who work in government don’t get over their you’re-stupid-I’m-smart approach to their jobs, they are going to destroy what little faith we as a people have left in government, as a recent poll demonstrated.

These self-appointed geniuses have the same DNA as everyone else and hence are prone to the same kinds of delusional thinking that plagues the rest of us. It’s just that these technocrats are in a position to bully the rest of us while hiding behind a wall of anonymity. And that’s the very thing that makes acronyms like NSA, IRS and FDA quite dangerous in the wrong hands.

And thus we have two times 23 more reasons we should be very careful about FDA, and indeed of all of government. I wonder if 23andMe can test for a gene for towering arrogance.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing